Breaks Categories: Stock Spotlights

MondayOct 11, 2021 1:42 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples…

Continue Reading

MondayOct 11, 2021 1:27 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

Continue Reading

FridayOct 08, 2021 11:36 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

Continue Reading

MondayOct 04, 2021 10:04 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, MCURF launched the minimum viable product (‘MVP’) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed…

Continue Reading

FridayOct 01, 2021 2:57 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Devices Addressing COVID, Research-Related Challenges in Neurological Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has solved issues related to offering neurological services during COVID. The new surge in the Delta variant highlights two problems in hospitals and the neurological market: staff shortages and contamination. “When it comes to neurological services during COVID, Brain Scientific has solved these issues with its two FDA-cleared EEG technologies — the NeuroCap and NeuroEEG. Easy to administer and disposable (the NeuroCap), these low-cost devices allow staff to provide EEGs at the patient’s bedside,” reads a recent article. Brain Scientific’s NeuroCap is disposable, and both devices…

Continue Reading

MondaySep 27, 2021 1:08 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes InMed CEO Eric A. Adams. “The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn process into larger vessels,” Adams said in a recent…

Continue Reading

MondaySep 27, 2021 11:58 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin usage in diseases with high unmet needs, including chronic pain, through its Psilocybin-For Neuropsychiatric Disorders (TM) (“PFN”) program. “With its three strategic initiatives — develop, protect and monetize — Tryp remains committed to utilizing FDA’s…

Continue Reading

FridaySep 24, 2021 1:37 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading.…

Continue Reading

ThursdaySep 23, 2021 2:21 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Proprietary Brain Diagnostics Devices Positioned to Profoundly Shift EEG Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is leveraging artificial intelligence (“AI”) and machine learning (“ML”) to improve diagnostic capability using a database of biomarkers that collect data on both normal and abnormal brain information. Brain Scientific’s use of AI and ML is part of its overall strategy to penetrate the rapidly growing electroencephalogram (“EEG”) market. The strategy includes developing its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. NeuroCap is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels that can be used to record EEGs in nearly any setting.…

Continue Reading

FridaySep 17, 2021 3:08 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Leveraging IoT Devices, AI Analytics to Provide Innovative Plant-Based Treatments

RYAH Group (CSE: RYAH), a connected device and big data and technology company, recently released a report outlining cannabis treatment options to address symptoms and conditions associated with HIV and AIDS. The report is based on information compiled by the RYAH Data Ecosystem, which enabled patients to submit data outlining symptoms they addressed with the use of cannabis, in addition to detailing specific cannabis strains used to treat those conditions. A recent article reads, “The ground-breaking report is part of RYAH’s data-driven mission to provide innovative plant-based medical treatments that leverage the use of IoT (Internet of Things) dose-measuring devices…

Continue Reading